X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-beats-first-quarter-revenue-profit-estimates-2024-04-25/
https://www.fiercepharma.com/marketing/astrazeneca-cries-havoc-over-ckds-hit-economies-environment
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211582
https://www.indianpharmapost.com/news/glenmark-to-launch-a-triple-drug-fdc-of-teneligliptin-dapagliflozin-metformin-in-india-for-type-2-diabetes-14798
https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-met-primary-endpoint-in-t2now-phase-iii-trial-one-of-the-largest-paediatric-type-2-diabetes-studies-performed-to-date.html
https://www.fiercepharma.com/pharma/bristol-myers-squibbs-reblozyl-chasing-4b-sales-expands-cover-anemia-patients-blood-cancer
https://www.fiercepharma.com/pharma/esc-2023-farxiga-studies-astrazeneca-shows-more-evidence-correlation-between-heart-and
https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-approved-china-reduce-risk-cardiovascular-death-hospitalisation-patients-with-symptomatic-chronic-heart-failure.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-gets-gcgi-approval-to-import-heart-failure-drug/articleshow/102085735.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://pharmafile.com/news/astrazenecas-xigduo-xr-approved-in-china-for-adults-with-type-2-diabetes/
https://www.pharmatimes.com/news/astrazenecas_dapagliflozin_recommended_by_nice_1491794
https://www.newswire.ca/news-releases/jamp-pharma-group-receives-health-canada-approval-for-prjamp-dapagliflozin-a-new-generic-alternative-for-the-treatment-of-type-2-diabetes-893001974.html
https://www.fiercepharma.com/pharma/fda-nod-astrazenecas-farxiga-gains-ground-heart-failure-race-jardiance
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211563
https://www.ema.europa.eu/en/documents/overview/dapagliflozin-viatris-epar-medicine-overview_en.pdf
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nppa-fixes-retail-price-of-74-drug-formulations/articleshow/98279741.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.fiercepharma.com/pharma/astrazenecas-farxiga-nabs-expanded-heart-failure-indication-eu#:~:text=AstraZeneca's%20SGLT2%20diabetes%20drug%20Forxiga,including%20mildly%20reduced%20and%20preserved.
https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquire-cincor-for-cardiorenal-asset.html
https://www.astrazeneca.com/media-centre/press-releases/2022/forxiga-chmp-opinion-for-symptomatic-chronic-hf.html
https://www.europeanpharmaceuticalreview.com/news/177359/dapagliflozin-approved-for-heart-failure-across-lvefs/
https://www.fiercepharma.com/marketing/eli-lilly-boehringer-launch-cuide-su-corazon-conversations-latina-women-heart-failure
https://www.pmlive.com/pharma_news/astrazenecas_farxiga_shows_symptom_benefit_for_heart_failure_patients_in_phase_3_trial_1480462
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-pharma-launches-drug-for-diabetic-patients-with-comorbidities/articleshow/94981411.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/forxiga-approved-in-china-for-ckd.html
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/farxiga-lowers-risk-cv-death-heart-failure.html
https://www.fiercepharma.com/marketing/lilly-and-boehringers-jardiance-poised-battle-azs-farxiga-chronic-kidney-disease-spherix
https://www.expresspharma.in/dapagliflozin-meets-primary-endpoint-in-deliver-phase-iii-trial/
https://www.pharmatimes.com/news/first_treatment_option_indicated_for_ckd_in_scotland_for_20_years_1448135
https://www.expresspharma.in/zydus-receives-final-approval-from-us-fda-for-dapagliflozin-tablets/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761125
https://www.pharmatimes.com/news/timely_intervention_first_chronic_kidney_disease_treatment_in_20_years_1387164
http://www.pharmafile.com/news/594712/diabetes-drug-dapagliflozin-recommended-nice-chronic-kidney-disease
https://www.europeanpharmaceuticalreview.com/news/165153/nice-recommend-dapagliflozin-for-treating-chronic-kidney-disease/
https://www.pharmatimes.com/news/nice_issues_draft_recommendation_for_new_kidney_disease_treatment_1383045
https://medicaldialogues.in/diabetes-endocrinology/news/dapagliflozin-reduces-risk-of-new-type-2-diabetes-in-ckd-patients-study-79182
https://health.economictimes.indiatimes.com/amp/news/pharma/sun-pharma-acquires-rights-to-trademarks-of-three-diabetes-drug-brands-in-india-from-astrazeneca/83033621
https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease
https://www.fiercepharma.com/pharma/astrazeneca-s-farxiga-wins-landmark-kidney-disease-nod-after-january-priority-review
http://www.pharmafile.com/news/576118/forxiga-accepted-use-within-nhs-scotland-chronic-heart-failure
https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-farxiga-covid-19-dare-19-phase-iii-trial.html
https://endpts.com/astrazenecas-farxiga-gets-rough-fda-review-date-for-groundbreaking-move-into-chronic-kidney-disease/
https://www.fiercepharma.com/pharma/astrazeneca-s-farxiga-scores-fda-priority-review-chronic-kidney-disease
Market Place
Share 
